Literature DB >> 24639042

Predictors of sildenafil effects on exercise capacity in adolescents and adults with Fontan circulation.

Alfred Hager1, Ruth Weber, Jan Müller, John Hess.   

Abstract

OBJECTIVE: A single dose of sildenafil improves exercise capacity in Fontan patients. However, a recent study failed to show a long-term effect of sildenafil. This study evaluated whether there are factors that might predict sildenafil effects.
METHODS: We studied 36 patients (16-42 years, 14 female) with univentricular heart after various modifications of the Fontan surgery (13 APC, 16 AVC, 7 TCPC). They performed two cardiopulmonary exercise tests, with at least 120 min rest and a single dose of 50 mg sildenafil in between.
RESULTS: After sildenafil administration, patients improved their peak oxygen uptake from 64.5 to 67.3 % predicted (p = 0.0003) without change in ventilatory efficiency ([Formula: see text] slope), oxygen saturation (SpO2) at rest or at peak exercise, respiratory exchange ratio. In addition, resting systolic blood pressure was slightly reduced after sildenafil administration. There was a moderate negative correlation of this improvement to baseline peak oxygen uptake (r = -0.395; p = 0.017). The change in peak oxygen uptake could not be correlated to time of surgery, type of surgery, NT-pro-BNP, or to other clinical data. Nevertheless, all four patients with NT-pro-BNP levels higher than 1,000 pg/ml had the most prominent improvements in exercise capacity.
CONCLUSIONS: Fontan patients have an improved exercise capacity after a single dose of sildenafil. Patients with worse baseline peak oxygen uptake profit more.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24639042     DOI: 10.1007/s00392-014-0694-2

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  25 in total

1.  Daily physical activity in adults with congenital heart disease is positively correlated with exercise capacity but not with quality of life.

Authors:  Jan Müller; John Hess; Alfred Hager
Journal:  Clin Res Cardiol       Date:  2011-09-21       Impact factor: 5.460

2.  Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome.

Authors:  Keiji Haseyama; Gengi Satomi; Satoshi Yasukochi; Hikoro Matsui; Yorikazu Harada; Shunji Uchita
Journal:  J Thorac Cardiovasc Surg       Date:  2006-11       Impact factor: 5.209

3.  Enalapril does not enhance exercise capacity in patients after Fontan procedure.

Authors:  A A Kouatli; J A Garcia; T M Zellers; E M Weinstein; L Mahony
Journal:  Circulation       Date:  1997-09-02       Impact factor: 29.690

4.  Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

5.  Sildenafil Increases Systemic Saturation and Reduces Pulmonary Artery Pressure in Patients with Failing Fontan Physiology.

Authors:  Gira S Morchi; D Dunbar Ivy; Mark C Duster; Lori Claussen; Kak-Chen Chan; Joseph Kay
Journal:  Congenit Heart Dis       Date:  2009-04       Impact factor: 2.007

6.  Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation.

Authors:  Sotiria C Apostolopoulou; John Papagiannis; Spyridon Rammos
Journal:  J Heart Lung Transplant       Date:  2005-08       Impact factor: 10.247

7.  The effect of bosentan in patients with a failing Fontan circulation.

Authors:  Caroline Ovaert; Daisy Thijs; Daniel Dewolf; Jaap Ottenkamp; Hugues Dessy; Philip Moons; Marc Gewillig; Luc Mertens
Journal:  Cardiol Young       Date:  2009-06-11       Impact factor: 1.093

8.  Exercise capacity, quality of life, and daily activity in the long-term follow-up of patients with univentricular heart and total cavopulmonary connection.

Authors:  Jan Müller; Florian Christov; Christian Schreiber; John Hess; Alfred Hager
Journal:  Eur Heart J       Date:  2009-08-18       Impact factor: 29.983

9.  Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.

Authors:  Hossein A Ghofrani; Robert Voswinckel; Frank Reichenberger; Horst Olschewski; Peter Haredza; Burcu Karadaş; Ralph T Schermuly; Norbert Weissmann; Werner Seeger; Friedrich Grimminger
Journal:  J Am Coll Cardiol       Date:  2004-10-06       Impact factor: 24.094

10.  Effects of sildenafil on exercise capacity in hypoxic normal subjects.

Authors:  Vitalie Faoro; Michel Lamotte; Gael Deboeck; Adriana Pavelescu; Sandrine Huez; Hervé Guenard; Jean-Benoît Martinot; Robert Naeije
Journal:  High Alt Med Biol       Date:  2007       Impact factor: 1.981

View more
  3 in total

1.  Estimating equations for cardiopulmonary exercise testing variables in Fontan patients: derivation and validation using a multicenter cross-sectional database.

Authors:  Ryan J Butts; Carolyn T Spencer; Lanier Jackson; Martha E Heal; Geoffrey Forbus; Thomas C Hulsey; Andrew M Atz
Journal:  Pediatr Cardiol       Date:  2014-09-02       Impact factor: 1.655

2.  Effect of Inhaled Nitric Oxide on Blood Flow Dynamics in Patients After the Fontan Procedure Using Cardiovascular Magnetic Resonance Flow Measurements.

Authors:  Heiner Latus; Bettina Gerstner; Gunter Kerst; Axel Moysich; Kerstin Gummel; Christian Apitz; Juergen Bauer; Dietmar Schranz
Journal:  Pediatr Cardiol       Date:  2015-11-07       Impact factor: 1.655

3.  Long-Term Serial Follow-Up of Pulmonary Artery Size and Wall Shear Stress in Fontan Patients.

Authors:  Sjoerd S M Bossers; Merih Cibis; Livia Kapusta; Wouter V Potters; Miranda M Snoeren; Jolanda J Wentzel; Adriaan Moelker; Willem A Helbing
Journal:  Pediatr Cardiol       Date:  2016-01-12       Impact factor: 1.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.